Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 208

1.

Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding.

Ptasinska A, Assi SA, Mannari D, James SR, Williamson D, Dunne J, Hoogenkamp M, Wu M, Care M, McNeill H, Cauchy P, Cullen M, Tooze RM, Tenen DG, Young BD, Cockerill PN, Westhead DR, Heidenreich O, Bonifer C.

Leukemia. 2012 Aug;26(8):1829-41. doi: 10.1038/leu.2012.49. Epub 2012 Feb 20.

2.

Identification of a dynamic core transcriptional network in t(8;21) AML that regulates differentiation block and self-renewal.

Ptasinska A, Assi SA, Martinez-Soria N, Imperato MR, Piper J, Cauchy P, Pickin A, James SR, Hoogenkamp M, Williamson D, Wu M, Tenen DG, Ott S, Westhead DR, Cockerill PN, Heidenreich O, Bonifer C.

Cell Rep. 2014 Sep 25;8(6):1974-1988. doi: 10.1016/j.celrep.2014.08.024. Epub 2014 Sep 18.

3.

The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.

Mandoli A, Singh AA, Prange KHM, Tijchon E, Oerlemans M, Dirks R, Ter Huurne M, Wierenga ATJ, Janssen-Megens EM, Berentsen K, Sharifi N, Kim B, Matarese F, Nguyen LN, Hubner NC, Rao NA, van den Akker E, Altucci L, Vellenga E, Stunnenberg HG, Martens JHA.

Cell Rep. 2016 Nov 15;17(8):2087-2100. doi: 10.1016/j.celrep.2016.08.082.

4.

Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.

Wichmann C, Chen L, Heinrich M, Baus D, Pfitzner E, Zörnig M, Ottmann OG, Grez M.

Cancer Res. 2007 Mar 1;67(5):2280-9.

5.

ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia.

Martens JH, Mandoli A, Simmer F, Wierenga BJ, Saeed S, Singh AA, Altucci L, Vellenga E, Stunnenberg HG.

Blood. 2012 Nov 8;120(19):4038-48. doi: 10.1182/blood-2012-05-429050. Epub 2012 Sep 14.

6.

The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia.

Vangala RK, Heiss-Neumann MS, Rangatia JS, Singh SM, Schoch C, Tenen DG, Hiddemann W, Behre G.

Blood. 2003 Jan 1;101(1):270-7. Epub 2002 Aug 29.

7.

Genome-wide co-occupancy of AML1-ETO and N-CoR defines the t(8;21) AML signature in leukemic cells.

Trombly DJ, Whitfield TW, Padmanabhan S, Gordon JA, Lian JB, van Wijnen AJ, Zaidi SK, Stein JL, Stein GS.

BMC Genomics. 2015 Apr 17;16:309. doi: 10.1186/s12864-015-1445-0.

8.

Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia.

Ter Elst A, Ma B, Scherpen FJ, de Jonge HJ, Douwes J, Wierenga AT, Schuringa JJ, Kamps WA, de Bont ES.

Cancer Res. 2011 Apr 1;71(7):2761-71. doi: 10.1158/0008-5472.CAN-10-0402. Epub 2011 Mar 29.

9.

Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.

Liu S, Klisovic RB, Vukosavljevic T, Yu J, Paschka P, Huynh L, Pang J, Neviani P, Liu Z, Blum W, Chan KK, Perrotti D, Marcucci G.

J Pharmacol Exp Ther. 2007 Jun;321(3):953-60. Epub 2007 Mar 26.

10.

The leukemogenic t(8;21) fusion protein AML1-ETO controls rRNA genes and associates with nucleolar-organizing regions at mitotic chromosomes.

Bakshi R, Zaidi SK, Pande S, Hassan MQ, Young DW, Montecino M, Lian JB, van Wijnen AJ, Stein JL, Stein GS.

J Cell Sci. 2008 Dec 1;121(Pt 23):3981-90. doi: 10.1242/jcs.033431. Epub 2008 Nov 11.

11.

RUNX1-ETO induces a type I interferon response which negatively effects t(8;21)-induced increased self-renewal and leukemia development.

DeKelver RC, Lewin B, Weng S, Yan M, Biggs J, Zhang DE.

Leuk Lymphoma. 2014 Apr;55(4):884-91. doi: 10.3109/10428194.2013.815351. Epub 2013 Jul 25.

12.

miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.

Fischer J, Rossetti S, Datta A, Eng K, Beghini A, Sacchi N.

Mol Cancer. 2015 Jan 23;14:7. doi: 10.1186/s12943-014-0283-z.

13.

RUNX1-ETO and RUNX1-EVI1 Differentially Reprogram the Chromatin Landscape in t(8;21) and t(3;21) AML.

Loke J, Assi SA, Imperato MR, Ptasinska A, Cauchy P, Grabovska Y, Soria NM, Raghavan M, Delwel HR, Cockerill PN, Heidenreich O, Bonifer C.

Cell Rep. 2017 May 23;19(8):1654-1668. doi: 10.1016/j.celrep.2017.05.005.

14.

Chromatin modifications induced by the AML1-ETO fusion protein reversibly silence its genomic targets through AML1 and Sp1 binding motifs.

Maiques-Diaz A, Chou FS, Wunderlich M, Gómez-López G, Jacinto FV, Rodriguez-Perales S, Larrayoz MJ, Calasanz MJ, Mulloy JC, Cigudosa JC, Alvarez S.

Leukemia. 2012 Jun;26(6):1329-37. doi: 10.1038/leu.2011.376. Epub 2012 Jan 13.

PMID:
22289984
15.

Genome-wide studies identify a novel interplay between AML1 and AML1/ETO in t(8;21) acute myeloid leukemia.

Li Y, Wang H, Wang X, Jin W, Tan Y, Fang H, Chen S, Chen Z, Wang K.

Blood. 2016 Jan 14;127(2):233-42. doi: 10.1182/blood-2015-03-626671. Epub 2015 Nov 6.

16.

Negative effects of GM-CSF signaling in a murine model of t(8;21)-induced leukemia.

Matsuura S, Yan M, Lo MC, Ahn EY, Weng S, Dangoor D, Matin M, Higashi T, Feng GS, Zhang DE.

Blood. 2012 Mar 29;119(13):3155-63. doi: 10.1182/blood-2011-04-350694. Epub 2012 Jan 5.

17.

Molecular targeting of aberrant transcription factors in leukemia: strategies for RUNX1/ETO.

Wichmann C, Grez M, Lausen J.

Curr Drug Targets. 2010 Sep;11(9):1181-91. Review.

PMID:
20583973
18.

A minicircuitry of microRNA-9-1 and RUNX1-RUNX1T1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia.

Fu L, Shi J, Liu A, Zhou L, Jiang M, Fu H, Xu K, Li D, Deng A, Zhang Q, Pang Y, Guo Y, Hu K, Zhou J, Wang Y, Huang W, Jing Y, Dou L, Wang L, Xu K, Ke X, Nervi C, Li Y, Yu L.

Int J Cancer. 2017 Feb 1;140(3):653-661. doi: 10.1002/ijc.30481. Epub 2016 Nov 10.

19.

Thrombopoietin/MPL participates in initiating and maintaining RUNX1-ETO acute myeloid leukemia via PI3K/AKT signaling.

Pulikkan JA, Madera D, Xue L, Bradley P, Landrette SF, Kuo YH, Abbas S, Zhu LJ, Valk P, Castilla LH.

Blood. 2012 Jul 26;120(4):868-79. doi: 10.1182/blood-2012-03-414649. Epub 2012 May 21.

20.

AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.

Pabst T, Mueller BU, Harakawa N, Schoch C, Haferlach T, Behre G, Hiddemann W, Zhang DE, Tenen DG.

Nat Med. 2001 Apr;7(4):444-51.

PMID:
11283671

Supplemental Content

Support Center